首页> 外文期刊>The Tohoku Journal of Experimental Medicine >Diagnostic usefulness of carbohydrate antigen-125 in cancerous and noncancerous peritoneal effusions.
【24h】

Diagnostic usefulness of carbohydrate antigen-125 in cancerous and noncancerous peritoneal effusions.

机译:碳水化合物抗原125在癌性和非癌性腹膜积液中的诊断有用性。

获取原文
获取原文并翻译 | 示例
           

摘要

Carbohydrate antigen-125 (CA-125) is a tumor marker that has been used for differential diagnosis of peritoneal malignancies. The aim of the present study was to evaluate the diagnostic usefulness of simultaneous quantification of CA-125 in peritoneal fluid and serum for abdominal cancer cases and noncancer diseases. Noncancer disease group included cirrhotic patients (n=28) and spontaneous bacterial peritonitis (SBP) patients (n=11). Abdominal cancer group was composed of histologically diagnosed various malignancies (n=10), such as gastric cancer. CA-125 levels were quantified by chemiluminescent enzyme immuno-assay. Diagnostic usefulness tests and receiver operating characteristics (ROC) curve analysis were performed for the levels of peritoneal fluid CA-125 (pCA-125) and serum CA-125 (sCA-125), and the ratio of pCA-125 to sCA-125 (p/sCA-125). The sCA-125 levels were significantly higher in noncancer patients than those in the cancer patients, while the pCA-125 levels showed no significant difference between the two groups. Notably, the p/sCA-125 ratio was significantly lower in the noncancer patients than that in the cancer patients. Area under the ROC curve was 0.267 for sCA-125, 0.542 for pCA-125 and 0.831 for p/sCA-125. The accepted cutoff values were the combination of values that gave the greatest diagnostic sensitivity plus specificity. Either sCA-125 or pCA-125 value gave lower diagnostic accuracy, whereas p/sCA-125 value demonstrated a significantly higher diagnostic accuracy (sensitivity-specificity pairs: 0.40-0.33 for sCA-125, 0.60-0.54 for pCA-125, and 0.80-0.72 for p/sCA-125, respectively). Hence, determination of p/sCA-125 improves the biochemical discrimination of abdominal cancerous cases from noncancerous diseases.
机译:碳水化合物抗原125(CA-125)是一种肿瘤标志物,已用于鉴别诊断腹膜恶性肿瘤。本研究的目的是评估腹膜液和血清中CA-125的同时定量对腹部癌病例和非癌性疾病的诊断价值。非癌疾病组包括肝硬化患者(n = 28)和自发性细菌性腹膜炎(SBP)患者(n = 11)。腹部癌组由组织学诊断为胃癌等各种恶性肿瘤(n = 10)组成。通过化学发光酶免疫测定法定量CA-125水平。对腹膜液CA-125(pCA-125)和血清CA-125(sCA-125)的水平以及pCA-125与sCA-125的比例进行了诊断有用性测试和受试者工作特征(ROC)曲线分析(p / sCA-125)。在非癌症患者中,sCA-125水平显着高于癌症患者,而在两组中,pCA-125水平没有显着差异。值得注意的是,非癌症患者的p / sCA-125比明显低于癌症患者。 sCA-125的ROC曲线下面积为0.267,pCA-125的为0.542,p / sCA-125的为0.831。可接受的临界值是给出最大诊断灵敏度和特异性的值的组合。 sCA-125或pCA-125值均会降低诊断准确度,而p / sCA-125值则显示出更高的诊断准确度(灵敏度-特异性对:sCA-125为0.40-0.33,pCA-125为0.60-0.54,以及对于p / sCA-125,分别为0.80-0.72)。因此,p / sCA-125的测定改善了腹部癌病例与非癌性疾病的生化鉴别。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号